Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A patient with an IOP greater than or equal to 20 mmHg related to unilateral or bilateral OH or OAG (primary open angle glaucoma, pseudo-exfoliative glaucoma, and pigmentary glaucoma), after a visual field exam~* Naive patients (i.e. never having been treated) and requiring treatment initiation~Exclusion Criteria:~* A patient with OH or OAG currently on treatment~* A patient with OH or OAG previously treated (regardless of the date treatment was discontinued)~* A patient with traumatic, inflammatory, or neovascular glaucoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Latanoprost group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).